1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

AdAlta CEO On Shark Antibody Technology

 
• By Lucie Ellis-Taitt

AdAlta CEO Sam Cobb discusses development of the company's novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.

Sam Cobb, managing director and CEO of Australian biotech AdAlta Ltd., talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead product, AD-114, in idiopathic pulmonary fibrosis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 
• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

 
• By Andrew McConaghie, Edwin Elmhirst, and Dexter Jie Yan

Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.

Glycomine Funds Phase IIb Rare Disease Trial With $115m Series C

 
• By Mandy Jackson

Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.

More from Business

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies

 
• By Mandy Jackson

Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.